M2 Archive: Preview


You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.


TheraCryf signs Master Service Agreement with Pharmaron for Orexin-1 addiction programme

TheraCryf plc (AIM: TCF), a clinical-stage drug development company focused on neuropsychiatry and oncology, announced on Monday that it has entered into a Master Service Agreement with Pharmaron UK Ltd (SZ: 300759 / HK: 3759.HK) to advance its Orexin-1 (Ox-1) addiction programme....  


If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search